The new tests enable clinicians to rapidly detect & differentiate between coronavirus SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus.
A new Independent Test Assessment Program will establish an accelerated pathway to support FDA evaluation of tests with potential for large-scale manufacturing.
OraSure Technologies' tests are authorized for over-the-counter use without a prescription, as well as for prescription and professional use in POC settings.